Antibacterial agent for systemic use.
Third generation cephalosporins. ATC code: J01D D02.
Ceftazidime inhibits the synthesis of the bacterial cell wall as a result of interaction with penicillin-binding proteins (PBPs). This causes disruption of the biosynthesis of the cell wall (peptidoglycan), which leads to lysis and death of bacterial cells.
Treatment of the following infections in adults and children, including newborns:
- hospital-acquired pneumonia;
- respiratory tract infections in patients with cystic fibrosis;
- bacterial meningitis;
- chronic otitis media;
- malignant otitis externa;
- complicated urinary tract infections;
- complicated skin and soft tissue infections;
- complicated intra-abdominal infections;
- bone and joint infections;
- dialysis-related peritonitis in patients on continuous ambulatory peritoneal dialysis.
For the treatment of bacteremia occurring in patients as a result of any of the above infections.
Ceftazidime can be used to treat patients with neutropenia and fever secondary to bacterial infection.
Ceftazidime can be used to prevent urinary tract infections during prostate surgeries (transurethral resection).
Posology and method of administration.
Adults and children with body weight ≥40 kg: 100–150 mg/kg BW every 8 hours daily; maximum 9 g per day.
Intramuscularly, intravenous bolus, intravenous infusion.
It could be given to newborns immediately after birth.
Vial with powder. One or 10 vials per box.